HRT Financial’s Iterum Therapeutics ITRM Stock Holding History

HRT Financial’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-890,083	Closed	-$26K	–	4773
2026 Q1	$26K	Buy	+890,083	New	+$223K	﹤0.01%	3543
2021 Q2	–	Sell	-26,632	Closed	-$563K	–	3167
2021 Q1	$563K	Buy	26,632 +25,962	+3,875%	+$618K	0.01%	1679
2020 Q4	$9K	Buy	+670	New	+$7.84K	﹤0.01%	1761

Other funds holding ITRM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

CCMW

Cypress Capital Management (Wyoming) Sheridan, Wyoming $120M AUM 63.01% 1-Year Est. Return

HRT Financial's ITRM Position: Q2 2026 in Review

HRT Financial sold out of Iterum Therapeutics (ITRM) in Q2 2026, closing a stake of 890,083 shares — an estimated $26K sold.

HRT Financial first reported a position in ITRM in Q4 2020 and held it in 3 quarters. The position peaked at $563K in Q1 2021. 2 funds tracked by Wall St. Rank hold ITRM as of Q2 2026.

HRT Financial reported no remaining Iterum Therapeutics position as of Q2 2026 after selling out during the quarter.
HRT Financial sold 890,083 Iterum Therapeutics shares in Q2 2026, an estimated $26K.
HRT Financial first reported a position in Iterum Therapeutics in Q4 2020 and held it in 3 quarters.
HRT Financial's Iterum Therapeutics position peaked at $563K in Q1 2021.
2 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.